{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:11:19Z","timestamp":1782843079627,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":417,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jtct.2022.01.011","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T12:38:58Z","timestamp":1642768738000},"page":"213.e1-213.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Risk of Cytomegalovirus Infection with Post-Transplantation Cyclophosphamide in Haploidentical and HLA-Matched Unrelated Donor Transplantation"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-4742","authenticated-orcid":false,"given":"Omer","family":"Jamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Dunn-Valadez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tylan","family":"Magnusson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"McGwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0003-0130","authenticated-orcid":false,"given":"Ayman","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.01.011_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.09.004","article-title":"Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review","volume":"342","author":"Ariza-Heredia","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jtct.2022.01.011_bib0002","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.011_bib0003","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2022.01.011_bib0004","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.011_bib0005","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.01.011_bib0006","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2217\/imt.15.70","article-title":"Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation","volume":"7","author":"Nishihori","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jtct.2022.01.011_bib0007","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fmicb.2019.01186","article-title":"Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients","volume":"10","author":"Stern","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jtct.2022.01.011_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2019-124659","article-title":"Post-transplantation cyclophosphamide after allogeneic hematopoietic stem cell transplantation: results of the prospective randomized HOVON-96 trial in recipients of matched related and unrelated donors","volume":"134(suppl_1)","author":"De Jong","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.011_bib0009","article-title":"Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation","author":"Jamy","year":"202196396","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.01.011_bib0010","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2022.01.011_bib0011","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.011_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3960\/jslrt.20040","article-title":"Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide","volume":"61","author":"Maeda","year":"2021","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.jtct.2022.01.011_bib0013","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.011_bib0014","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.3324\/haematol.2016.149880","article-title":"Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide","volume":"101","author":"Goldsmith","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.01.011_bib0015","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2010-03-273508","article-title":"Immune monitoring with iTAg MHC tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study","volume":"116","author":"Gratama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.011_bib0016","first-page":"e318","article-title":"Characterization of CMV-specific CD4+ T-cell reconstitution following stem cell transplantation through the use of HLA class II-peptide tetramers identifies patients at high risk of recurrent CMV reactivation","volume":"100","author":"Raeiszadeh","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.01.011_bib0017","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1399-3062.2011.00626.x","article-title":"Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Borchers","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2022.01.011_bib0018","first-page":"S305","article-title":"CMV and BK virus reactivation in post transplant cyclophosphamide (PTCY) after allogeneic MUD, MRD and haploidentical transplant","volume":"23","author":"Wang","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.011_bib0019","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.011_bib0020","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2236.2236","article-title":"Favorable immune reconstitution profile after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide","volume":"128","author":"Jamy","year":"2016","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.jtct.2022.01.011_bib0021","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1016\/j.bbmt.2018.12.528","article-title":"Dynamics of immune cell reconstitution in allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide (PTCy)","volume":"25","author":"Rambaldi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.011_bib0022","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s12185-010-0597-6","article-title":"Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion","volume":"91","author":"Schmidt-Hieber","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.01.011_bib0023","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","article-title":"Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients","volume":"118","author":"Elmaagacli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.011_bib0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/civ215","article-title":"Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices","volume":"61","author":"Erard","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2022.01.011_bib0025","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1182\/blood-2011-10-386995","article-title":"Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function","volume":"119","author":"Foley","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.011_bib0026","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.011_bib0027","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fonc.2019.00888","article-title":"The presence of a CMV immunodominant allele in the recipient is associated with increased survival in CMV positive patients undergoing haploidentical hematopoietic stem cell transplantation","volume":"9","author":"Grosso","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2022.01.011_bib0028","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.01.011_bib0029","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ajh.25993","article-title":"Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: a prospective comparative study","volume":"96","author":"Cho","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.01.011_bib0030","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.01.011_bib0031","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-018-0598-0","article-title":"Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT","volume":"11","author":"Santoro","year":"2018","journal-title":"J Hematol Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722000318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722000318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:01:46Z","timestamp":1763002906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722000318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2666636722000318"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.01.011","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Cytomegalovirus Infection with Post-Transplantation Cyclophosphamide in Haploidentical and HLA-Matched Unrelated Donor Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}